This study was an open label, three period, fixed sequence study in healthy male and female subjects performed at a single study center.~The study comprised:~Screening during Days -28 to -2 (both inclusive).~Three treatment periods separated by a washout period of at least 10 days.~Duration of Treatment:~The duration of participation for each subject was approximately 2 months and 2 weeks (including the screening period).
The purpose of this study is:~To investigate CYP2C9 inhibition by BIA 5-1058 through the assessment of its effect on the Pharmacokinetic (PK) of S-warfarin, a substrate of CYP2C9.~To assess the effect of warfarin on the PK of BIA 5-1058.